ZA989138B - Conjugates of galactose-binding lectins and clostridial neurotoxins as analgesics - Google Patents

Conjugates of galactose-binding lectins and clostridial neurotoxins as analgesics

Info

Publication number
ZA989138B
ZA989138B ZA989138A ZA989138A ZA989138B ZA 989138 B ZA989138 B ZA 989138B ZA 989138 A ZA989138 A ZA 989138A ZA 989138 A ZA989138 A ZA 989138A ZA 989138 B ZA989138 B ZA 989138B
Authority
ZA
South Africa
Prior art keywords
galactose
pain
agents
analgesics
conjugates
Prior art date
Application number
ZA989138A
Other languages
English (en)
Inventor
Michael John Duggan
John Andrew Chaddock
Original Assignee
Speywood Lab Ltd
Microbiological Res Authority
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Speywood Lab Ltd, Microbiological Res Authority filed Critical Speywood Lab Ltd
Publication of ZA989138B publication Critical patent/ZA989138B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pain & Pain Management (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Anesthesiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
ZA989138A 1997-10-08 1998-10-07 Conjugates of galactose-binding lectins and clostridial neurotoxins as analgesics ZA989138B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9721189.0A GB9721189D0 (en) 1997-10-08 1997-10-08 Analgesic conjugates

Publications (1)

Publication Number Publication Date
ZA989138B true ZA989138B (en) 1999-05-27

Family

ID=10820129

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA989138A ZA989138B (en) 1997-10-08 1998-10-07 Conjugates of galactose-binding lectins and clostridial neurotoxins as analgesics

Country Status (13)

Country Link
US (2) US7052702B1 (fr)
EP (1) EP0996468B1 (fr)
JP (1) JP4629225B2 (fr)
AT (1) ATE240747T1 (fr)
AU (1) AU741456B2 (fr)
CA (1) CA2306350C (fr)
DE (1) DE69814858T2 (fr)
DK (1) DK0996468T3 (fr)
ES (1) ES2198750T3 (fr)
GB (1) GB9721189D0 (fr)
PT (1) PT996468E (fr)
WO (1) WO1999017806A1 (fr)
ZA (1) ZA989138B (fr)

Families Citing this family (86)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9508204D0 (en) * 1995-04-21 1995-06-07 Speywood Lab Ltd A novel agent able to modify peripheral afferent function
US8012491B2 (en) * 1996-08-23 2011-09-06 Syntaxin, Ltd. Recombinant toxin fragments
GB9617671D0 (en) * 1996-08-23 1996-10-02 Microbiological Res Authority Recombinant toxin fragments
US7192596B2 (en) * 1996-08-23 2007-03-20 The Health Protection Agency Ipsen Limited Recombinant toxin fragments
GB9721189D0 (en) * 1997-10-08 1997-12-03 Speywood Lab The Limited Analgesic conjugates
US20040071736A1 (en) * 1998-08-25 2004-04-15 Health Protection Agency Methods and compounds for the treatment of mucus hypersecretion
US20080249019A1 (en) * 1998-08-25 2008-10-09 Syntaxin, Ltd. Treatment of mucus hypersecretion
GB9907429D0 (en) * 1999-03-31 1999-05-26 Microbiological Res Authority Modulation of C-fibre activity
US7740868B2 (en) 1999-08-25 2010-06-22 Allergan, Inc. Activatable clostridial toxins
ES2277854T5 (es) 1999-08-25 2011-02-04 Allergan, Inc. Neurotoxinas recombinantes activables.
US20090018081A1 (en) * 1999-08-25 2009-01-15 Allergan, Inc. Activatable clostridial toxins
GB9922554D0 (en) 1999-09-23 1999-11-24 Microbiological Res Authority Inhibition of secretion from non-neuronal cells
US6113915A (en) * 1999-10-12 2000-09-05 Allergan Sales, Inc. Methods for treating pain
US7368532B2 (en) 1999-12-02 2008-05-06 Syntaxin Limited Constructs for delivery of therapeutic agents to neuronal cells
DK1234043T3 (da) * 1999-12-02 2004-07-19 Health Prot Agency Konstruktion for afgivelse af terapeutiske midler til neuroceller
US7838008B2 (en) 1999-12-07 2010-11-23 Allergan, Inc. Methods for treating diverse cancers
US7838007B2 (en) 1999-12-07 2010-11-23 Allergan, Inc. Methods for treating mammary gland disorders
WO2001047512A2 (fr) * 1999-12-08 2001-07-05 Fluoro Probe, Inc. Technique analgesique dans le cas d'une douleur liee a une localisation pathologique interne
US6500436B2 (en) 2000-01-19 2002-12-31 Allergan, Inc. Clostridial toxin derivatives and methods for treating pain
US7138127B1 (en) * 2000-01-19 2006-11-21 Allergan, Inc. Clostridial toxin derivatives and methods for treating pain
US6641820B1 (en) * 2000-01-19 2003-11-04 Allergan, Inc. Clostridial toxin derivatives and methods to treat pain
US6821520B2 (en) 2000-02-15 2004-11-23 Allergan, Inc. Clostridial toxin therapy for Hashimoto's thyroiditis
US6464986B1 (en) 2000-04-14 2002-10-15 Allegan Sales, Inc. Method for treating pain by peripheral administration of a neurotoxin
JP2004521067A (ja) * 2000-06-28 2004-07-15 サンダース，イラ 動物（哺乳動物）における有用な用途を目的とする破傷風毒素の使用方法
DE10035156A1 (de) * 2000-07-19 2002-02-07 Biotecon Ges Fuer Biotechnologische Entwicklung & Consulting Mbh Proteinkomplex als Vehikel für oral verfügbare Protein-Arzneimittel
US6903187B1 (en) * 2000-07-21 2005-06-07 Allergan, Inc. Leucine-based motif and clostridial neurotoxins
US6831059B2 (en) 2000-10-20 2004-12-14 Allergan, Inc. Compositions and methods for treating gonadotrophin related illnesses
GB0108332D0 (en) * 2001-04-03 2001-05-23 Univ Durham Lectin directed prodrug delivery system
US7022329B2 (en) * 2002-02-25 2006-04-04 Allergan, Inc. Method for treating neurogenic inflammation pain with botulinum toxin and substance P components
US7140371B2 (en) 2002-03-14 2006-11-28 Allergan, Inc. Surface topography method for determining effects of a botulinum toxin upon a muscle and for comparing botulinum toxins
US6688311B2 (en) 2002-03-14 2004-02-10 Allergan, Inc. Method for determining effect of a clostridial toxin upon a muscle
GB0213383D0 (en) * 2002-06-11 2002-07-24 Cambridge Biotechnology Ltd Therapeutic conditions
US8071550B2 (en) 2003-03-03 2011-12-06 Allergan, Inc. Methods for treating uterine disorders
US7172764B2 (en) * 2003-11-17 2007-02-06 Allergan, Inc. Rescue agents for treating botulinum toxin intoxications
US9211248B2 (en) 2004-03-03 2015-12-15 Revance Therapeutics, Inc. Compositions and methods for topical application and transdermal delivery of botulinum toxins
US7514088B2 (en) 2005-03-15 2009-04-07 Allergan, Inc. Multivalent Clostridial toxin derivatives and methods of their use
US7811584B2 (en) * 2004-06-30 2010-10-12 Allergan, Inc. Multivalent clostridial toxins
EP1982996A1 (fr) * 2004-09-01 2008-10-22 Allergan, Inc. Toxines clostridiennes dégradables
US7179474B2 (en) 2004-09-03 2007-02-20 Allergan, Inc. Methods for treating a buttock deformity
US7429386B2 (en) 2004-09-03 2008-09-30 Allergan, Inc. Stretch mark treatment
US8603779B2 (en) 2004-12-01 2013-12-10 Syntaxin, Ltd. Non-cytotoxic protein conjugates
GB0426397D0 (en) 2004-12-01 2005-01-05 Health Prot Agency Fusion proteins
US8778634B2 (en) 2004-12-01 2014-07-15 Syntaxin, Ltd. Non-cytotoxic protein conjugates
GB0426394D0 (en) * 2004-12-01 2005-01-05 Health Prot Agency Fusion proteins
US8512984B2 (en) 2004-12-01 2013-08-20 Syntaxin, Ltd. Non-cytotoxic protein conjugates
US8399400B2 (en) 2004-12-01 2013-03-19 Syntaxin, Ltd. Fusion proteins
US7659092B2 (en) 2004-12-01 2010-02-09 Syntaxin, Ltd. Fusion proteins
EP1861419B1 (fr) * 2005-03-15 2011-06-29 Allergan, Inc. Toxines clostridiales modifiees dotees de capacites de ciblage ameliorees pour des systemes de recepteurs de toxines clostridiales endogenes
US8021859B2 (en) * 2005-03-15 2011-09-20 Allergan, Inc. Modified clostridial toxins with altered targeting capabilities for clostridial toxin target cells
US7419675B2 (en) 2005-05-26 2008-09-02 Allergan, Inc. Method for treating peritoneal adhesions
GB0610867D0 (en) 2006-06-01 2006-07-12 Syntaxin Ltd Treatment of pain
JP2009543556A (ja) 2006-07-11 2009-12-10 アラーガン、インコーポレイテッド 増強した転位置能力および増強したターゲティング活性を有する改変クロストリジウム毒素
WO2008008803A2 (fr) 2006-07-11 2008-01-17 Allergan, Inc. Toxines clostridiennes modifiées à capacité de translocation améliorée et à activité modifiée de ciblage des cellules cibles des toxines clostridiennes
SG185338A1 (en) * 2007-10-23 2012-11-29 Allergan Inc Methods of treating urogenital-neurological disorders using modified clostridial toxins
WO2011023213A1 (fr) * 2009-08-28 2011-03-03 Merz Pharma Gmbh & Co. Kgaa Agents de chimiodénervation modifiés
GB201108108D0 (en) * 2011-05-16 2011-06-29 Syntaxin Ltd Therapeutic fusion proteins
DK3372239T3 (da) 2012-05-30 2021-02-01 Harvard College Manipuleret botulinumneurotoksin
US20140056870A1 (en) 2012-08-27 2014-02-27 Allergan, Inc. Fusion proteins
US9005628B2 (en) 2012-10-04 2015-04-14 Dublin City University Biotherapy for pain
BR112015003591B1 (pt) 2012-11-21 2022-02-01 Ipsen Bioinnovation Limited Usos de lys-c e métodos para fabricação de um polipeptídeo proteoliticamente processado
GB201312317D0 (en) 2013-07-09 2013-08-21 Syntaxin Ltd Cationic neurotoxins
US9216210B2 (en) 2013-12-23 2015-12-22 Dublin City University Multiprotease therapeutics for chronic pain
US10647750B2 (en) 2015-01-09 2020-05-12 Ipsen Bioinnovation Limited Cationic neurotoxins
EP3274364B1 (fr) 2015-03-26 2021-08-04 President and Fellows of Harvard College Neurotoxine botulique ingéniérisée
GB201517450D0 (en) 2015-10-02 2015-11-18 Ipsen Biopharm Ltd Method
EP3263710A1 (fr) 2016-07-01 2018-01-03 Ipsen Biopharm Limited Production de neurotoxines clostridiales activées
US11117935B2 (en) 2016-08-24 2021-09-14 President And Fellows Of Harvard College Engineered botulinum neurotoxin
WO2018038301A1 (fr) 2016-08-26 2018-03-01 Hugel Inc. Formulation liquide stabilisée de toxine botulique et procédé pour sa préparation
PL3529616T3 (pl) 2016-10-20 2024-03-18 President And Fellows Of Harvard College Testy in vitro i komórkowe do pomiaru aktywności neurotoksyn botulinowych
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
EP3470054B1 (fr) 2017-10-11 2023-09-20 Hugel Inc. Techniques de formulation de microstructure pour toxine botulinique
US10525111B2 (en) 2017-10-12 2020-01-07 Hugel, Inc. Microstructure formulation techniques for botulinum toxin
US10792400B2 (en) 2017-10-12 2020-10-06 Hugel Inc. Microstructure formulation techniques for botulinum toxin
WO2019162696A1 (fr) 2018-02-26 2019-08-29 Ipsen Biopharm Limited Utilisation d'ultrasons pour guider l'injection de protéase non-cytotoxique
GB201815817D0 (en) 2018-09-28 2018-11-14 Ispen Biopharm Ltd Clostridial neurotoxins comprising and exogenous activation loop
EP3660509B1 (fr) 2018-11-29 2022-03-09 Hugel Inc. Procédé basé sur des cellules permettant de déterminer une activité de toxine botulinique
GB201900621D0 (en) 2019-01-16 2019-03-06 Ipsen Biopharm Ltd Labelled polypeptides
GB201914034D0 (en) 2019-09-30 2019-11-13 Ipsen Biopharm Ltd Treatment of neurological disorders
GB202100566D0 (en) 2021-01-15 2021-03-03 Ipsen Biopharm Ltd Treatment of brain damage
GB202104294D0 (en) 2021-03-26 2021-05-12 Ipsen Biopharm Ltd Clostridial neurotoxins comprising an exogenous activation loop
CN117396217A (zh) 2021-03-30 2024-01-12 益普生生物制药有限公司 无催化活性的梭菌神经毒素用于疼痛和炎性疾病的治疗
WO2022208091A1 (fr) 2021-03-30 2022-10-06 Ipsen Biopharm Limited Traitement de troubles inflammatoires et de la douleur
GB202116795D0 (en) 2021-11-22 2022-01-05 Ipsen Biopharm Ltd Treatment of visceral pain
WO2023105289A1 (fr) 2021-12-06 2023-06-15 Dublin City University Méthodes et compositions pour le traitement de la douleur
GB202214232D0 (en) 2022-09-28 2022-11-09 Ispen Biopharm Ltd Clostridial neurotoxins comprising an activating exogenous protease cleavage site
GB202214229D0 (en) 2022-09-28 2022-11-09 Ipsen Biopharm Ltd Clostridial neurotoxins comprising an activating endosomal protease cleavage site

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4792447A (en) 1981-07-23 1988-12-20 Board Of Regents, The University Of Texas System Anti-immunoglobulin toxin conjugates useful in the treatment of B cell tumors
US5668255A (en) 1984-06-07 1997-09-16 Seragen, Inc. Hybrid molecules having translocation region and cell-binding region
US4873346A (en) 1985-09-20 1989-10-10 The Upjohn Company Substituted benzothiazoles, benzimidazoles, and benzoxazoles
JPH05502880A (ja) 1989-12-22 1993-05-20 セラジェン・インコーポレーテッド トランスロケーション領域および細胞結合領域を有するハイブリッド分子
WO1992015327A1 (fr) 1991-03-08 1992-09-17 Protein Design Labs, Inc. Immunotoxines bicatenaires de recombinaison
WO1993004191A1 (fr) 1991-08-15 1993-03-04 Neorx Corporation Conjugues de toxines non cytolytiques
US5433946A (en) 1991-10-11 1995-07-18 Health Research Inc. Synthesis and utilization of therapeutic agents for the treatment of lysosomal storage diseases
WO1993015766A1 (fr) 1992-02-10 1993-08-19 Seragen, Inc. Desensibilisation concernant des allergenes specifiques
US6235313B1 (en) 1992-04-24 2001-05-22 Brown University Research Foundation Bioadhesive microspheres and their use as drug delivery and imaging systems
DE4242902A1 (de) 1992-12-18 1994-06-23 Madaus Ag Verfahren zur Herstellung von Lektinkonzentraten aus Mistelextrakten und daraus hergestellte standardisierte Präparate zur Erhöhung der natürlichen Immunresistenz und für die Verwendung in der Tumor-Therapie
WO1994028923A1 (fr) 1993-06-10 1994-12-22 Allergan, Inc. Toxines de botulinum multiples utilisees dans le traitement de troubles et etats neuromusculaires
EP1477183B1 (fr) 1993-12-28 2005-11-02 Allergan, Inc. Composante neurotoxique de la toxine botulinique pour la modulation des secretions controllées par le système cholinergique
JP3497554B2 (ja) 1994-03-25 2004-02-16 日本臓器製薬株式会社 新規プリン誘導体及びその薬学的に許容される塩
US5766605A (en) 1994-04-15 1998-06-16 Mount Sinai School Of Medicine Of The City University Of New York Treatment of autonomic nerve dysfunction with botulinum toxin
JP3523879B2 (ja) 1994-05-31 2004-04-26 アレルガン インコーポレイテッド 輸送タンパク質用クロストリジウム属細菌毒素の修飾
GB9411138D0 (en) 1994-06-03 1994-07-27 Microbiological Res Authority Toxin assay
EP1041149B8 (fr) 1994-10-24 2007-10-03 Allergan, Inc. Vaccin et antitoxines pour le traitement et la prévention de maladies causées par C. difficile
US5721207A (en) * 1995-04-18 1998-02-24 Innapharma, Inc. Method for treatment of pain
GB9508204D0 (en) 1995-04-21 1995-06-07 Speywood Lab Ltd A novel agent able to modify peripheral afferent function
WO1997013410A1 (fr) 1995-10-13 1997-04-17 Boston Medical Center Corporation Molecules hybrides contenant des ligands amides fixant les polypeptides
WO1997018790A2 (fr) 1995-11-22 1997-05-29 The Research And Development Institute, Inc. Agents therapeutiques et de diagnostic pour traiter les infections microbiennes
US7192596B2 (en) 1996-08-23 2007-03-20 The Health Protection Agency Ipsen Limited Recombinant toxin fragments
US5760149A (en) 1996-08-23 1998-06-02 Elf Atochem North America, Inc. Poly(monoperoxycarbonates)
GB9617671D0 (en) 1996-08-23 1996-10-02 Microbiological Res Authority Recombinant toxin fragments
AU4245097A (en) 1996-08-28 1998-03-19 Ophidian Pharmaceuticals, Inc. Multivalent vaccine for (clostridium botulinum) neurotoxin
DE19735105A1 (de) 1997-08-13 1999-03-04 Univ Albert Ludwigs Freiburg Transportsystem zur Einbringung von Proteinen in Zielzellen mit Hilfe eines Fusionsproteins, Nucleinsäurekonstrukte kodierend für die Komponenten des Transportsystems und Arzneimittel, die Komponenten des Transportsystems umfassen
GB9721189D0 (en) * 1997-10-08 1997-12-03 Speywood Lab The Limited Analgesic conjugates
PT1084146E (pt) 1998-05-13 2003-02-28 Biotecon Gesells Biotec Entwic Proteina hibrida para inibicao de desgranulacao de mastocitos e seu uso
WO2000004926A2 (fr) 1998-07-22 2000-02-03 Osprey Pharmaceuticals Limited Traitement de degats tissulaires secondaires, etats inflammatoires et autres troubles, et compositions a cet effet
GB9818548D0 (en) 1998-08-25 1998-10-21 Microbiological Res Authority Treatment of mucas hypersecretion
US20040071736A1 (en) 1998-08-25 2004-04-15 Health Protection Agency Methods and compounds for the treatment of mucus hypersecretion
GB9824282D0 (en) 1998-11-05 1998-12-30 Microbiological Research Agenc Delivery of superoxide dismutase to neuronal cells
GB9907429D0 (en) 1999-03-31 1999-05-26 Microbiological Res Authority Modulation of C-fibre activity
US7368532B2 (en) 1999-12-02 2008-05-06 Syntaxin Limited Constructs for delivery of therapeutic agents to neuronal cells

Also Published As

Publication number Publication date
US7052702B1 (en) 2006-05-30
DE69814858D1 (de) 2003-06-26
PT996468E (pt) 2003-09-30
US20060121056A1 (en) 2006-06-08
GB9721189D0 (en) 1997-12-03
DE69814858T2 (de) 2004-03-11
CA2306350A1 (fr) 1999-04-15
JP2001518522A (ja) 2001-10-16
ATE240747T1 (de) 2003-06-15
EP0996468B1 (fr) 2003-05-21
US7452543B2 (en) 2008-11-18
DK0996468T3 (da) 2003-09-15
JP4629225B2 (ja) 2011-02-09
EP0996468A1 (fr) 2000-05-03
ES2198750T3 (es) 2004-02-01
AU741456B2 (en) 2001-11-29
AU9357498A (en) 1999-04-27
WO1999017806A1 (fr) 1999-04-15
CA2306350C (fr) 2008-09-02

Similar Documents

Publication Publication Date Title
ZA989138B (en) Conjugates of galactose-binding lectins and clostridial neurotoxins as analgesics
MXPA03000576A (es) Motivo a base de leucina y neurotoxinas clostridial.
AU1225099A (en) Protease variants and compositions
PL323006A1 (en) Derivatives of toxin clostridium capable to modify peripheral functions of afferent sensory fibres
TR199701705T1 (xx) Trigliserid ya�lar�n i�lenmesinde hareketsiz enzim ve kullan�m�.
FI963861A (fi) Alkalinen Bacillus-amylaasi
NZ311274A (en) Mutant alpha-amylase
WO1999029876A3 (fr) Alpha-amylases mutantes de bacillus licheniformis
WO2001077951A8 (fr) Systeme et procedes pour administrer un plan de retraite de groupe
NZ507874A (en) Dressing with one or more elastic sections and adhesive on one side
WO2002044199A3 (fr) Neurotoxines possedant une specificite accrue a l'egard de cibles
AU7645100A (en) Wound care device
WO2002040506A3 (fr) Neurotoxines clostridiales modifiees a persistance biologique alteree
BG103977A (en) Low molecular rotamase enzymic activity inhibitors
DE60028359D1 (de) Chromogenes medium zum nachweis von staphylococcus aureus
PT1311504E (pt) Tetrazolil-fenil-acetamidas activadoras da glucoquinase
ES2149982T3 (es) Acidos naftalenoboronicos.
DE69435307D1 (de) Bazillus Thuringiensis und dessen insektizide Proteine
WO2000064405A3 (fr) Traitement des cheveux a l'aide d'enzymes cibles
BR9604825A (pt) Citostáticos modificados por carboidratos
PT1234043E (pt) Construcoes para a entrega de agentes terapeuticos a celulas neuronais
AU2003295769A1 (en) Treatment of mammalian reaction to ige interactions
AU2002216621A1 (en) Optical isolator with low insertion loss and minimized polarization mode dispersion
DK177791D0 (da) Tensidfrie, faste enzympraeparater omfattende protease som virksomt enzym
AU1885700A (en) Device for holding socks or stockings in pairs